VBI Vaccines Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Cambridge MA United States (2001)

Organization Overview

First Clinical Trial
2006
NCT04531098
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Variation Biotechnologies Inc. | VBI Vaccines | VBI Vaccines Inc.

Active Ingredients

Drugs in Phase 4 Trials (1)

hepatitis b vaccine (recombinant) (recombivax) (3 trials)

Drugs in Phase 3 Trials (2)

engerix-b (2 trials)

sci-b-vac (2 trials)

Drugs in Phase 2 Trials (3)

brii-179 (1 trial)

interferon alfa-1b (1 trial)

vir-2218 (1 trial)

Drugs in Phase 1 Trials (4)

vbi-1501 (1 trial)

vbi-1901 (1 trial)

vbi-2902a (1 trial)

vbi-2905a (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cytomegalovirus Infections (Phase 1)

Glioblastoma (Phase 1)

Hepatitis (Phase 3)

Hepatitis A (Phase 3)

Hepatitis B (Phase 4)

Infections (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 9
  • # of Trial APIs: 10